leisure time -WSS

leisure time

author：explore 2025-10-01 14:40:23 - browse：663

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： National associations that represent hospice owe an apology

focus

WSS

ARCH Venture Partners is raising $3 billion for a life sciences fund

SAMSHA loosens regulations on methadone treatment centers

DeSantis wants to import drugs. Biden’s FDA blasted his plan

CDC says it’s too soon to assess risk posed by Covid subvariant

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Congressmen charge Covid hearing ‘could have been an email’

knowledge

leisure time

knowledge

Psychedelics group wrestles with new pharma identity

Vertigo drug brings hope for rare neuron disorder, Niemann

State Dept. review finds Biden bears some blame for Afghanistan failures

Former Pear Therapeutics executives start new VC firm

Hollywood unions extend contract negotiations for actors

Hospital at home shows how to bring innovation to health care

ChatGPT in medicine: STAT answers readers' burning questions

Kellogg’s is going to war over Mexico’s nutrition label rules

Apple is now the first public company to be valued at $3 trillion

People can get long Covid without testing positive for virus: Study

knowledge

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Wegovy improves function in certain heart failure patients

What we need to know about Arena Bioworks

What we need to know about Arena Bioworks

Covid misinformation case heads to Supreme Court

General Catalyst, Summa Health deal will turn on physician buy

knowledge

focus

knowledge

knowledge